Multiple Sclerosis Stocks List

Recent Signals

Date Stock Signal Type
2021-04-09 ALKS Bollinger Band Squeeze Range Contraction
2021-04-09 ALKS MACD Bullish Signal Line Cross Bullish
2021-04-09 ALKS 200 DMA Support Bullish
2021-04-09 BCLI NR7 Range Contraction
2021-04-09 BCLI Narrow Range Bar Range Contraction
2021-04-09 FREQ Boomer Sell Setup Bearish Swing Setup
2021-04-09 FREQ Narrow Range Bar Range Contraction
2021-04-09 FREQ 1,2,3 Retracement Bearish Bearish Swing Setup
2021-04-09 FREQ MACD Bullish Signal Line Cross Bullish
2021-04-09 FREQ Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-09 FWP 50 DMA Support Bullish
2021-04-09 GMAB Bollinger Band Squeeze Range Contraction
2021-04-09 GMAB Stochastic Reached Overbought Strength
2021-04-09 IMUX NR7 Range Contraction
2021-04-09 IMUX NR7-2 Range Contraction
2021-04-09 IMUX Narrow Range Bar Range Contraction
2021-04-09 IONS Stochastic Reached Oversold Weakness
2021-04-09 IONS New 52 Week Closing Low Bearish
2021-04-09 MYO Stochastic Reached Oversold Weakness
2021-04-09 MYO 180 Bearish Setup Bearish Swing Setup
2021-04-09 MYO Narrow Range Bar Range Contraction
2021-04-09 PRTK Crossed Above 20 DMA Bullish
2021-04-09 PRTK Volume Surge Other
2021-04-09 PRTK Wide Range Bar Range Expansion
2021-04-09 PRTK MACD Bullish Signal Line Cross Bullish
2021-04-09 PRTK Expansion Pivot Buy Setup Bullish Swing Setup
2021-04-09 PRTK Pocket Pivot Bullish Swing Setup
2021-04-09 PRTK Crossed Above 50 DMA Bullish
2021-04-09 PSTI Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-09 PSTI 1,2,3 Retracement Bearish Bearish Swing Setup
2021-04-09 SNY Pocket Pivot Bullish Swing Setup
2021-04-09 SNY New Uptrend Bullish
2021-04-09 SNY 180 Bullish Setup Bullish Swing Setup
2021-04-09 SYN Narrow Range Bar Range Contraction
2021-04-09 SYN NR7 Range Contraction
2021-04-09 TEVA NR7 Range Contraction
2021-04-09 TEVA Bollinger Band Squeeze Range Contraction
2021-04-09 VCNX Narrow Range Bar Range Contraction

Recent News for Multiple Sclerosis Stocks

Date Stock Title
Apr 11 IONS 3 Critical Things Investors Should Look for Before Buying Clinical-Stage Biotech Stocks
Apr 9 BIIB Biogen Announces Two New Nominees for Election to Board of Directors
Apr 9 GMAB FDA accepts Genmab, Seagen's tisotumab vedotin BLA application for review
Apr 9 GMAB Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9 SNY Sanofi targets mRNA based medicine with acquisition of Tidal Therapeutics
Apr 9 SNY Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
Apr 9 SNY Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor
Apr 9 SNY Sanofi confirms partial response for cancer therapy in mid-stage study
Apr 9 MGLN Magellan (MGLN) Expands in Precision Oncology With Trapelo
Apr 9 BIIB Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action
Apr 9 FREQ Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Apr 9 PSTI Cathie Wood Seems To Be Bullish On Elon Musk-Led SpaceX's 3D Printer Supplier Velo3D — And More
Apr 9 SNY Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
Apr 8 SNY Study shows wearables could detect COVID-19 earlier
Apr 8 BIIB Biotech Stocks Could Use A Win — Will The First Quarter Offer That?
Apr 8 BIIB Is It Too Late to Buy Biogen (BIIB) Stock?
Apr 8 BIIB Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis
Apr 8 ALKS Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
Apr 8 BIIB Biogen inks BAT1806 licensing deal in rheumatoid arthritis
Apr 8 TEVA Teva’s Seffalair And BroPair Spiromax Receive Approval In EU

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially as the disease advances.While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as being triggered by a viral infection. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks. Medications used to treat MS, while modestly effective, can have side effects and be poorly tolerated. Physical therapy can help with people's ability to function. Many people pursue alternative treatments, despite a lack of evidence of benefit. The long-term outcome is difficult to predict, with good outcomes more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Life expectancy is on average 5 to 10 years lower than that of an unaffected population.Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally with rates varying widely in different regions and among different populations. That year about 18,900 people died from MS, up from 12,000 in 1990. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. MS was first described in 1868 by Jean-Martin Charcot. The name multiple sclerosis refers to the numerous scars (sclerae—better known as plaques or lesions) that develop on the white matter of the brain and spinal cord. A number of new treatments and diagnostic methods are under development.

More about Multiple Sclerosis
Browse All Tags